Details of the Drug Combinations

General Information of This Drug (ID: DMSWLA3)

Drug Name

Darapladib DMSWLA3

Synonyms

SB 480848; Darapladib (USAN)

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Discontinued in Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Darapladib + Midazolam	DCRCOMN	Midazolam	Atherosclerosis	[2]
Diltiazem + Darapladib	DCQXK0H	Diltiazem	Atherosclerosis	[3]
Rosuvastatin + Darapladib	DCSCSQE	Rosuvastatin	Atherosclerosis	[4]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6696).
2	ClinicalTrials.gov (NCT01873339) Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects
3	ClinicalTrials.gov (NCT01852565) Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).
4	ClinicalTrials.gov (NCT01751074) To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers